Publications
80
Citations
1,572
Est. group size
~3
Recurring co-author estimate
Active years
50
Publishing since 1977
Typically publishes in teams of ~9 · 23% small-team papers (≤3 authors) · across 10 venues
- Human iPSC-Based Modeling Identifies Epigenetic Regulation at the <i>KCNQ1</i> Locus During Early Islet Development That Contributes to Lower β-Cell Mass
Diabetes · 2026
- The impact of coadministration of venlafaxine, citalopram or gabapentin on the metabolic activation of tamoxifen
Breast Cancer Research and Treatment · 2025
- A mixed-methods study characterizing experiences of medical oncologists’ use of gonadotropin-releasing hormone agonists for treatment of breast cancer
Breast Cancer Research and Treatment · 2025
- Abstract P1-04-02: Longitudinal multi-omics study reveals potential targets against chemotherapy induced peripheral neuropathy during taxane treatment
Clinical Cancer Research · 2025
- Optimising therapy and avoiding overtreatment in breast cancer
The Lancet Oncology · 2024
- Neighborhood socioeconomic deprivation and patient-reported outcomes in symptom management trials for women with breast cancer
Breast Cancer Research and Treatment · 2024
- Abstract PO1-11-06: Evaluating Symptom Clusters in Patients with Breast Cancer Experiencing Aromatase Inhibitor-Associated Musculoskeletal Symptoms
Cancer Research · 2024
- Abstract PS04-08: Sociodemographic Risk Factors and Prediction of Aromatase Inhibitor Non-Adherence in Women with Breast Cancer Enrolled in SWOG S1105
Cancer Research · 2024
- Genetic variations that influence paclitaxel pharmacokinetics and intracellular effects that may contribute to chemotherapy-induced neuropathy: A narrative review
Frontiers in Pain Research · 2023
- Abstract OT1-17-01: Protocol Description of Genetics and Inflammatory Markers to predict Chemotherapy-Induced Peripheral Neuropathy among Early Stage Breast Cancer Patients Receiving Taxane Therapy – GENIE Study
Cancer Research · 2023
- Abstract PD12-03: Predictors of pain reduction in trials of interventions for aromatase inhibitor (AI)-associated musculoskeletal symptoms (AIMSS)
Cancer Research · 2021
- Abstract SP059: Toxicities of breast cancer treatment
Cancer Research · 2021
- Role of Patient and Disease Factors in Adjuvant Systemic Therapy Decision Making for Early-Stage, Operable Breast Cancer: Update of the ASCO Endorsement of the Cancer Care Ontario Guideline
Journal of Clinical Oncology · 2019
- Abstract P1-11-04: Association between body mass index (BMI) and response to duloxetine for aromatase inhibitor (AI)-associated musculoskeletal symptoms (AIMSS)
Cancer Research · 2019
- Abstract GS3-02: Invasive disease-free survival and gene expression signatures in CALGB (Alliance) 40601, a randomized phase III neoadjuvant trial of dual HER2-targeting with lapatinib added to chemotherapy plus trastuzumab
Cancer Research · 2018
- Cancer Research×20
- Breast Cancer Research and Treatment×4
- Journal of Clinical Oncology×2
- JAMA Oncology×2
- Research Square×2
- Kathy D. Miller
Medicine · Indiana University
- Ewa Mrózek
Medicine · The Ohio State University
- Daniel L. Hertz
Medicine · University of Michigan
- Erica Cantor
Medicine · Indiana University
- Guanglong Jiang
Medicine · Indiana University
This profile was generated automatically from public scholarly data (OpenAlex). Group size and activity levels are estimates derived from co-authorship patterns.
Last updated Jul 25, 2026.
Claim or correct this profile